Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-12-16 Share Issue/Capital Cha…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Share Issue/Capital Change Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and details the completion of the first tranche of a multi-tranche financing, including the amount secured (€21.4 million) and the intended use of proceeds. It also announces changes to the Board of Directors. This content strongly indicates a corporate announcement regarding financing activities and management changes, rather than a full regulatory report (like 10-K or IR) or a simple announcement of a report's publication (RPA/RNS). The specific mention of securing funds and capital structure changes aligns best with the 'Capital/Financing Update' category (CAP). While management changes are mentioned, the primary focus and bulk of the text concern the financing transaction.
2024-12-16 English
Inventiva obtient 21,4 millions d'euros complétant la première tranche du financement multi-tranches annoncé précédemment d'un montant maximum de 348 millions d'euros
Share Issue/Capital Change Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and details a specific financial transaction: Inventiva raising 21.4 million euros to complete the first tranche of a multi-tranche financing facility, including the issuance of new shares and warrants (Actions Nouvelles T1bis and BSA T1bis). It discusses the use of proceeds (advancing clinical trials) and changes in the Board of Directors. This content directly relates to fundraising, capital structure changes, and the issuance of new securities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions an AGM resolution authorizing the action, the primary focus is the financing event itself, not the AGM materials or voting results.
2024-12-16 French
Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 11 décembre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document title is "Résultats des votes de l'Assemblée Générale Mixte des actionnaires – 11 décembre 2024" (Results of the votes of the Combined General Meeting of Shareholders – December 11, 2024). The text explicitly details the adoption status of numerous resolutions (numbered 1 through 59, though only up to 38 are shown in the provided snippet) voted upon during this meeting, including detailed vote counts ('Pour', 'Contre', 'Abstention') and quorum information. This content directly corresponds to the official results of a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-12-12 French
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states in the title and opening paragraph that it contains the "Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024." This content details the outcome (Adopted/Rejected) for numerous numbered resolutions voted upon by shareholders. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an Annual Report (10-K), an Earnings Release (ER), or a proxy solicitation (PSI), but the final results of the meeting.
2024-12-12 English
Inventiva publie ses informations financières du 3ème trimestre 2024¹
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses informations financières du 3ème trimestre 2024" (Inventiva publishes its financial information for the 3rd quarter of 2024) and explicitly details key financial metrics (cash, revenue, financing activities) for the first nine months of 2024, ending September 30, 2024. This content structure—a detailed financial update for a period shorter than a full year—is characteristic of an Interim/Quarterly Report (IR). Although it contains elements of an Earnings Release (ER) by summarizing key figures, the depth of the cash flow statement analysis and subsequent financial details strongly suggests it is the comprehensive quarterly report rather than just the initial press release highlights. It is not a 10-K (Annual Report) because the period is Q3, not the full year. It is not an RPA because it contains the full financial data, not just an announcement of its availability. 9M 2024
2024-11-21 French
Inventiva reports 2024 Third Quarter Financial Information¹
Earnings Release Classification · 99% confidence The document is explicitly titled "Inventiva reports 2024 Third Quarter Financial Information" and provides key financial highlights (cash position as of September 30, 2024, revenues for the first nine months of 2024) along with subsequent financing and operational updates. This structure—reporting on a specific fiscal period (Q3/Nine Months) with key financial metrics—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on reporting the financial results for the period rather than just announcing that a full report is coming (which would be RPA/RNS), and it contains the core financial data, it fits best as an Interim Report (IR). However, the title uses the term 'Financial Information' and focuses heavily on cash and key operational updates, which is often the content of an Earnings Release (ER) which precedes the full, detailed Quarterly Report (IR). Given the content is a summary of results for the first nine months (Q3), it aligns closely with the definition of an Interim/Quarterly Report (IR). The document is comprehensive enough to be more than just the initial highlights (ER), but it is not explicitly labeled as the full 'Interim Report' like a 10-Q would be in the US context. Since it covers the first nine months (Q3), 'IR' (Interim / Quarterly Report) is the most appropriate classification over 'ER' (Earnings Release, which is usually just the highlights). 9M 2024
2024-11-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.